We propose that the addition of anti-CSF-1R antibody to the combination of GVAX therapy and anti-PD-1 antibody can improve the survival outcome of PDAC by further altering the myeloid population and creating a more anti-tumor immune environment. The gene discussed is CSF1R; the disease is neoplasm.